GACVS sub-committee on nOPV2 safety

(established December 2020)

Rules of engagement

(to be read in conjunction with the **ToRs** of the GACVS sub-committee on nOPV2 safety).

Roles and responsibilities of participants of the working group

1. All participants are bound to confidentiality and are required to declare any potential conflicts of interest for assessment by the secretariat at the outset of their appointment and at any time thereafter when their potential conflicts may change. Summary statements of declaration of interests will be web-posted.

2. Members of the sub-committee, participate in full in the discussions and drafting of recommendations of the sub-committee. Members participate in their personal capacity, not as representatives of their institution.

3. *Ad hoc* experts can be assigned for particular tasks or areas of work. They are not members of the sub-committee but serve as expert resource persons. They are not involved in formulation of draft recommendations. Interests will nevertheless be declared and confidentiality rules apply.

Interaction with nOPV2 vaccine manufacturer and experts

1. Representative(s) from the nOPV2 manufacturer can be invited to present to the sub-committee on the status of their work and future development plans. Information provided will be treated confidentially and can include non-published or proprietary information.

2. As a rule, nOPV2 manufacturer representatives will only participate in specific sessions to which they are invited and will otherwise not participate in the deliberations of the working group.

3. The sub-committee may also issue invitations to representatives of relevant clinical trial networks related to nOPV2.

4. Experts in specific areas (such as immunology, immunoassays, animal studies, vaccine safety) can be invited if the specific need arises to share state of knowledge information or help with any analysis as needed.